RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.

David BaruaAfrin SultanaMd Nahidul IslamFergus CoxAnanya GuptaSanjeev Gupta

Published in: BMC cancer (2023)

Our results suggest that RRM2 and CDC6 downstream of XBP1 contribute to endocrine resistance in ER-positive breast cancer. XBP1-gene signature is associated with poor outcome and response to tamoxifen in ER-positive breast cancer.

Keyphrases

positive breast cancer
estrogen receptor
cell cycle
endoplasmic reticulum
breast cancer cells
copy number
transcription factor